Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (1-10 of 662) with videos related to

Pageof 67
Sort By:
The Lancet. Oncology|October 23, 2010
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemiaPeter Valent
Current Cancer Drug Targets|November 11, 2010
Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial conceptPeter Valent
Best Practice & Research. Clinical Haematology|May 29, 2020
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and managementPeter Valent
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|June 4, 2018
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical ImplicationsPeter Valent
Wiener Klinische Wochenschrift|September 20, 2002
Mast cell leukemia--a rare form of myeloid leukemiaPeter Valent
Haematologica|January 3, 2020
KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6Peter Valent
The Journal of Allergy and Clinical Immunology. in Practice|September 10, 2022
Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic AlgorithmPeter Valent
Leukemia & Lymphoma|October 31, 2006
Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromesPeter Valent
Haematologica|October 6, 2011
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbiditiesPeter Valent
Hematology. American Society of Hematology. Education Program|December 6, 2015
Diagnosis and management of mastocytosis: an emerging challenge in applied hematologyPeter Valent
Pageof 67

Showing results (1-10 of 662) with videos related to

Sort By:
Pageof 67
The Lancet. Oncology|October 23, 2010
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemiaPeter Valent
Current Cancer Drug Targets|November 11, 2010
Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial conceptPeter Valent
Best Practice & Research. Clinical Haematology|May 29, 2020
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and managementPeter Valent
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|June 4, 2018
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical ImplicationsPeter Valent
Wiener Klinische Wochenschrift|September 20, 2002
Mast cell leukemia--a rare form of myeloid leukemiaPeter Valent
Haematologica|January 3, 2020
KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6Peter Valent
The Journal of Allergy and Clinical Immunology. in Practice|September 10, 2022
Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic AlgorithmPeter Valent
Leukemia & Lymphoma|October 31, 2006
Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromesPeter Valent
Haematologica|October 6, 2011
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbiditiesPeter Valent
Hematology. American Society of Hematology. Education Program|December 6, 2015
Diagnosis and management of mastocytosis: an emerging challenge in applied hematologyPeter Valent
Pageof 67